FibroBiologics, Inc. (FBLG)
FBLG moved a median of -0.71% 30 minutes after news, and -1.85% by the close. How FBLG actually reacts to news — the realized, point-in-time move the market made, measured across 303 labeled events over the last three years with zero look-ahead.
FBLG’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.04% | 41% | 296 |
| 30-min | -0.71% | 42% | 302 |
| 60-min | -1.25% | 39% | 302 |
| to close | -1.85% | 42% | 302 |
| Middle 50% of FBLG reactions | -3.87% to +1.96% |
|---|---|
| Median reaction (30-min) | -0.71% |
| Measured reactions | 303 |
Half of all FibroBiologics, Inc. news events land between -3.87% and +1.96% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How FBLG reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 11 | -2.53% | 36% | +3.92% |
| Rating reiterations | 57 | +0.43% | 53% | -0.42% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how FBLG ranks against every other measured name →
That’s how FBLG usually reacts — get an email when it moves on news →Email me when FBLG moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to FBLG's baseline. Nothing else.
Recent FBLG events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs | Press release | PR Newswire | -4.34% | -5.00% | |
| Form D FibroBiologics, Inc. | SEC filing · Form D | SEC EDGAR | — | -4.01% | |
| Form POS AM FibroBiologics, Inc. | SEC filing · Form POS | SEC EDGAR | -4.34% | -5.00% | |
| Form 8-K FibroBiologics, Inc. For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.80% | |
| FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body | Press release | PR Newswire | -0.43% | -1.72% | |
| FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity | Press release | PR Newswire | +2.17% | -5.07% | |
| Form 8-K FibroBiologics, Inc. For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | -2.06% | -6.85% | |
| FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer | Press release | PR Newswire | -1.30% | -2.94% | |
| Form D FibroBiologics, Inc. | SEC filing · Form D | SEC EDGAR | +0.00% | -0.69% | |
| Form 8-K FibroBiologics, Inc. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | -7.10% | |
| Form DEFA14A FibroBiologics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.00% | |
| Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications | Press release | ACCESS Newswire | -2.78% | -5.00% | |
| FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing | Press release | PR Newswire | -2.39% | -2.22% | |
| FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media | Press release | PR Newswire | +0.58% | +21.96% | |
| FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial | Press release | PR Newswire | +0.00% | +3.47% | |
| FibroBiologics Regains Compliance with Nasdaq Trading Rules | Press release | PR Newswire | +5.04% | +1.44% | |
| FibroBiologics Appoints Leigh Steinberg to Board of Directors | Press release | PR Newswire | +2.06% | -6.25% | |
| Form 8-K FibroBiologics, Inc. For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | +2.06% | -6.25% | |
| FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease | Press release | PR Newswire | +0.43% | +5.74% | |
| FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints | Press release | PR Newswire | -3.67% | +4.59% | |
| FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets | Press release | PR Newswire | -1.01% | +4.04% | |
| FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage | Press release | PR Newswire | +2.35% | +2.12% | |
| FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate | Press release | PR Newswire | +2.78% | +9.79% | |
| Form 10-Q FibroBiologics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.78% | +9.79% | |
| Form DEF 14A FibroBiologics, Inc. For: Sep 17 | SEC filing · Form DEF | SEC EDGAR | -3.91% | -5.28% | |
| Form 8-K FibroBiologics, Inc. For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | -1.90% | -8.18% | |
| Form EFFECT FibroBiologics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.01% | +1.57% | |
| Form PRE 14A FibroBiologics, Inc. For: Sep 17 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -3.58% | |
| Form S-3 FibroBiologics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +7.42% | |
| FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors | Press release | PR Newswire | +0.00% | +3.73% | |
| Form 8-K FibroBiologics, Inc. For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | — | +3.73% | |
| FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial | Press release | PR Newswire | -2.30% | -5.64% | |
| FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | Press release | PR Newswire | +1.64% | +18.46% | |
| FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | Press release | PR Newswire | +1.64% | +18.46% | |
| Form 8-K FibroBiologics, Inc. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +1.64% | +18.46% | |
| Form D FibroBiologics, Inc. | SEC filing · Form D | SEC EDGAR | +1.64% | +18.46% | |
| FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | Press release | PR Newswire | +0.38% | +8.73% | |
| Form 8-K FibroBiologics, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +2.53% | +2.55% | |
| FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing | Press release | GlobeNewswire | +0.82% | +5.47% | |
| FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers | Press release | GlobeNewswire | +1.02% | -6.49% | |
| FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers | Press release | GlobeNewswire | +0.95% | +1.91% | |
| FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting | Press release | GlobeNewswire | +0.00% | -1.87% | |
| FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics | Press release | GlobeNewswire | -1.85% | +0.93% | |
| FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus | Press release | GlobeNewswire | -4.29% | -5.71% | |
| Form 8-K FibroBiologics, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.86% | +0.78% | |
| FibroBiologics CEO Issues Letter to Shareholders | Press release | GlobeNewswire | -4.22% | -6.34% | |
| Form 8-K FibroBiologics, Inc. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -4.22% | -6.34% | |
| Form ARS FibroBiologics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -4.22% | -6.34% | |
| Form DEF 14A FibroBiologics, Inc. For: May 05 | SEC filing · Form DEF | SEC EDGAR | -4.22% | -6.34% | |
| Form DEFA14A FibroBiologics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -4.22% | -6.34% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the FBLG section they belong to.
Where else FBLG is measured.
FBLG earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is FibroBiologics, Inc.'s median reaction calculated?
Every labeled FBLG news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 303 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of FBLG's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does FBLG's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.